.jpg)
.jpg)
.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
The FDA has rejected Milestone Pharmaceuticals’ application for approval of Card...
European Medicines Agency says risks of potentially fatal side effects from dona...
CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opp...
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now ...
BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xV...
Template for response to list of questions/list of outstanding issues: Quality /...
Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechan...
Day 80 assessment report - Non-clinical template with guidance Rev. 03.25 - Revamp
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attr...
Having stripped back its workforce, antibiotics biotech Spero Therapeutics conti...
EMA concludes review of weight management medicine Mysimba
Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab,...
Human medicines European public assessment report (EPAR): Jubereq, denosumab, St...
Human medicines European public assessment report (EPAR): Ryjunea, Status: Opinion
Human medicines European public assessment report (EPAR): Kisunla, donanemab, St...
Referral: Mysimba, naltrexone,bupropion Article 20 procedures CHMP opinion, 27/0...
Summary of opinion: Calquence, 27/03/2025 Positive
Five new medicines recommended for approvalEMA’s human medicines committee (CHMP...
Summary of opinion: Flucelvax, 27/03/2025 Positive